Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response.
Information on the effects of imatinib mesylate (IM) on the non-clonal bone marrow (BM) cell compartment is scanty. We have analyzed the gene expression profile of BM hematopoietic cells after IM therapy in 20 patients with chronic myeloid leukaemia (CML) in complete cytogenetic response (CCyR) and compared it with that of normal volunteer donors by oligonucleotide microarrays. In CCyR CML samples, IM induces a decrease in proliferation as well as increase in apoptosis and ubiquitination in residual non-clonal BM cells. In addition, IM diminishes cell-to-cell adhesion and downregulates the expression of the erythropoietin (EPO) receptor gene. The latter was confirmed by RT-PCR.
Sanchez-Guijo
Fermin M
FM
Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain.
Hernandez
Jesus M
JM
Lumbreras
Eva
E
Morais
Patricia
P
Santamaría
Carlos
C
Garcia
Juan-Luis
JL
Gutierrez
Norma C
NC
Miguel
Jesus F San
JF
Del Cañizo
Maria-Consuelo
MC
D001483:Base Sequence; D001549:Benzamides; D001854:Bone Marrow Cells / Q000187:drug effects*; D017931:DNA Primers; D020869:Gene Expression Profiling; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D017467:Receptors, Erythropoietin / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D001549:Benzamides; D017931:DNA Primers; D010879:Piperazines; D011743:Pyrimidines; D017467:Receptors, Erythropoietin; D000068877:Imatinib Mesylate